{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T17:53:23Z","timestamp":1764093203212,"version":"3.45.0"},"reference-count":169,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780443294143"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.apcsb.2025.08.010","type":"book-chapter","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T11:10:19Z","timestamp":1756552219000},"page":"1-27","source":"Crossref","is-referenced-by-count":0,"title":["Protein misfolding in hemophilia"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.apcsb.2025.08.010_bib1","doi-asserted-by":"crossref","DOI":"10.1177\/1076029619888293","article-title":"Identification of the intron 22 and intron 1 inversions of the factor VIII gene in Iraqi kurdish patients with hemophilia A","volume":"26","author":"Abdulqader","year":"2020","journal-title":"Clinical and Applied Thrombosis\/Hemostasis: Official Journal of the International Academy of Clinical and Applied Thrombosis\/Hemostasis"},{"issue":"8","key":"10.1016\/bs.apcsb.2025.08.010_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/biom10081141","article-title":"Co-chaperones in targeting and delivery of misfolded proteins to the 26S proteasome","volume":"10","author":"Abildgaard","year":"2020","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.08.010_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/diseases11010030","article-title":"Protein misfolding and aggregation in proteinopathies: Causes, mechanism and cellular response","volume":"11","author":"Ajmal","year":"2023","journal-title":"Diseases"},{"issue":"10","key":"10.1016\/bs.apcsb.2025.08.010_bib4","doi-asserted-by":"crossref","first-page":"6859","DOI":"10.3390\/molecules15106859","article-title":"Dealing with misfolded proteins: Examining the neuroprotective role of molecular chaperones in neurodegeneration","volume":"15","author":"Ali","year":"2010","journal-title":"Molecules (Basel, Switzerland)"},{"issue":"21","key":"10.1016\/bs.apcsb.2025.08.010_bib5","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1182\/blood.2021011753","article-title":"A new \u201cFIX\u201d for hemophilia b gene therapy","volume":"137","author":"Almeida-Porada","year":"2021","journal-title":"Blood"},{"key":"10.1016\/bs.apcsb.2025.08.010_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.pdpdt.2019.101598","article-title":"Detection of hemophilia by fluorescence spectroscopy: A photodiagnosis approach","volume":"29","author":"AlSalhi","year":"2020","journal-title":"Photodiagnosis and Photodynamic Therapy"},{"issue":"4","key":"10.1016\/bs.apcsb.2025.08.010_bib7","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1055\/s-0038-1637690","article-title":"Activation of endoplasmic reticulum stress and unfolded protein response in congenital factor VII deficiency","volume":"118","author":"Andersen","year":"2018","journal-title":"Thrombosis and Haemostasis"},{"issue":"3","key":"10.1016\/bs.apcsb.2025.08.010_bib8","first-page":"141","article-title":"Extended half-life coagulation factors: A new era in the management of hemophilia patients","volume":"36","author":"Ar","year":"2019","journal-title":"Turkish Journal of Hematology"},{"issue":"11","key":"10.1016\/bs.apcsb.2025.08.010_bib9","doi-asserted-by":"crossref","first-page":"a007526","DOI":"10.1101\/cshperspect.a007526","article-title":"Protein folding and quality control in the ER","volume":"3","author":"Araki","year":"2011","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"issue":"7","key":"10.1016\/bs.apcsb.2025.08.010_bib10","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.2174\/1871527313666140917095514","article-title":"Protein misfolding and aggregation in alzheimer\u2019s disease and type 2 diabetes mellitus","volume":"13","author":"Ashraf","year":"2014","journal-title":"CNS & Neurological Disorders Drug Targets"},{"issue":"3","key":"10.1016\/bs.apcsb.2025.08.010_bib11","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1182\/blood.V95.3.820.003k32_820_828","article-title":"Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector","volume":"95","author":"Balagu\u00e9","year":"2000","journal-title":"Blood"},{"issue":"12","key":"10.1016\/bs.apcsb.2025.08.010_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20123036","article-title":"Molecular mechanisms and determinants of innovative correction approaches in coagulation factor deficiencies","volume":"20","author":"Balestra","year":"2019","journal-title":"International Journal of Molecular Sciences"},{"issue":"6","key":"10.1016\/bs.apcsb.2025.08.010_bib13","first-page":"535","article-title":"Diagnosis and care of patients with mild haemophilia: Practical recommendations for clinical management","volume":"16","author":"Benson","year":"2018","journal-title":"Blood Transfusion"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.08.010_bib14","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1080\/19336896.2022.2095185","article-title":"Creutzfeldt-Jakob disease after COVID-19: infection-induced prion protein misfolding? A case report","volume":"16","author":"Bernardini","year":"2022","journal-title":"Prion"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.08.010_bib15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-021-00278-x","article-title":"Haemophilia","volume":"7","author":"Berntorp","year":"2021","journal-title":"Nature Reviews Disease Primers"},{"issue":"18","key":"10.1016\/bs.apcsb.2025.08.010_bib16","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1182\/blood.2021010864","article-title":"The cost-effectiveness of gene therapy for severe hemophilia B: A microsimulation study from the United States perspective","volume":"138","author":"Bolous","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/bs.apcsb.2025.08.010_bib17","first-page":"19","article-title":"Blood coagulation factors v and VIII: Molecular mechanisms of procofactor activation","volume":"2","author":"Bos","year":"2010","journal-title":"Journal of Coagulation Disorders"},{"issue":"2","key":"10.1016\/bs.apcsb.2025.08.010_bib18","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/mp.55.2.127","article-title":"Haemophilia a and haemophilia B: Molecular insights","volume":"55","author":"Bowen","year":"2002","journal-title":"Molecular Pathology: MP"},{"issue":"6","key":"10.1016\/bs.apcsb.2025.08.010_bib19","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1055\/s-0042-1758870","article-title":"Factor VIII and factor IX activity measurements for hemophilia diagnosis and related treatments","volume":"49","author":"Bowyer","year":"2023","journal-title":"Seminars in Thrombosis and Hemostasis"},{"issue":"6","key":"10.1016\/bs.apcsb.2025.08.010_bib20","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1111\/hae.14884","article-title":"A next generation FVIII mimetic bispecific antibody, Mim8, the impact on non-factor VIII related haemostasis assays","volume":"29","author":"Bowyer","year":"2023","journal-title":"Haemophilia: the Official Journal of the World Federation of Hemophilia"},{"key":"10.1016\/bs.apcsb.2025.08.010_bib21","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2147\/JBM.S390521","article-title":"RNAi for the treatment of people with hemophilia: Current evidence and patient selection","volume":"14","author":"Boyce","year":"2023","journal-title":"Journal of Blood Medicine"},{"key":"10.1016\/bs.apcsb.2025.08.010_bib22","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/B978-0-12-407704-1.00005-1","article-title":"Endoplasmic reticulum and the unfolded protein response: Dynamics and metabolic integration","volume":"301","author":"Bravo","year":"2013","journal-title":"International Review of Cell and Molecular Biology"},{"issue":"3","key":"10.1016\/bs.apcsb.2025.08.010_bib23","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/(SICI)1098-1004(1999)14:3<186::AID-HUMU2>3.0.CO;2-J","article-title":"Protein misfolding and degradation in genetic diseases","volume":"14","author":"Bross","year":"1999","journal-title":"Human Mutation"},{"issue":"27","key":"10.1016\/bs.apcsb.2025.08.010_bib24","doi-asserted-by":"crossref","first-page":"24451","DOI":"10.1074\/jbc.M111.238758","article-title":"Enhanced biosynthesis of coagulation factor VIII through diminished engagement of the unfolded protein response","volume":"286","author":"Brown","year":"2011","journal-title":"The Journal of Biological Chemistry"},{"issue":"11","key":"10.1016\/bs.apcsb.2025.08.010_bib25","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1182\/blood.V112.11.3087.3087","article-title":"Exploiting ER stress to eliminate inhibitor antibodies in hemophilia","volume":"112","author":"Callaghan","year":"2008","journal-title":"Blood"},{"issue":"9","key":"10.1016\/bs.apcsb.2025.08.010_bib26","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.3324\/haematol.2019.221093","article-title":"Hemophilia a and B: Molecular and clinical similarities and differences","volume":"104","author":"Castaman","year":"2019","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/bs.apcsb.2025.08.010_bib27","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1007\/s00277-022-04972-y","article-title":"Usefulness of anti-factor VIII IgG ELISA in acquired hemophilia a follow-up","volume":"101","author":"Chansavang","year":"2022","journal-title":"Annals of Hematology"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.08.010_bib28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40259-017-0255-0","article-title":"Gene therapy for hemophilia: Progress to date","volume":"32","author":"Chapin","year":"2018","journal-title":"BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy"},{"key":"10.1016\/bs.apcsb.2025.08.010_bib29","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.thromres.2021.02.027","article-title":"The spectrum of FVIII gene variants detected by next generation sequencing in 236 Chinese non-inversion hemophilia a pedigrees","volume":"202","author":"Chen","year":"2021","journal-title":"Thrombosis Research"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.08.010_bib30","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/s41392-023-01570-w","article-title":"Endoplasmic reticulum stress: Molecular mechanism and therapeutic targets","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"12","key":"10.1016\/bs.apcsb.2025.08.010_bib31","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1016\/j.jtha.2023.10.005","article-title":"Cellular stress and coagulation factor production: When more is not necessarily better","volume":"21","author":"Chen","year":"2023","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"9","key":"10.1016\/bs.apcsb.2025.08.010_bib32","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1111\/jth.15793","article-title":"Structural insights into blood coagulation factor VIII: Procoagulant complexes, membrane binding, and antibody inhibition","volume":"20","author":"Childers","year":"2022","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"2","key":"10.1016\/bs.apcsb.2025.08.010_bib33","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.1055\/s-0044-1785524","article-title":"Disease burden, clinical outcomes, and quality of life in people with hemophilia a without inhibitors in Europe: Analyses from CHESS II\/CHESS PAEDs","volume":"8","author":"Chowdary","year":"2024","journal-title":"TH Open"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.08.010_bib34","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/nar\/26.1.285","article-title":"The human gene mutation database","volume":"26","author":"Cooper","year":"1998","journal-title":"Nucleic Acids Research"},{"issue":"14","key":"10.1016\/bs.apcsb.2025.08.010_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411846","article-title":"Four decades of carrier detection and prenatal diagnosis in hemophilia A: Historical overview, state of the art and future directions","volume":"24","author":"Dardik","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/bs.apcsb.2025.08.010_bib36","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.thromres.2023.10.001","article-title":"Treatment of congenital coagulopathies, from biologic to biotechnological drugs: The relevance of gene editing (CRISPR\/Cas)","volume":"231","author":"De Pablo-Moreno","year":"2023","journal-title":"Thrombosis Research"},{"issue":"15","key":"10.1016\/bs.apcsb.2025.08.010_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23158283","article-title":"The vascular endothelium and coagulation: Homeostasis, disease, and treatment, with a focus on the von willebrand factor and factors VIII and v","volume":"23","author":"De Pablo-Moreno","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"issue":"7","key":"10.1016\/bs.apcsb.2025.08.010_bib38","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1111\/j.1538-7836.2010.03864.x","article-title":"Health-related quality of life among adult patients with moderate and severe von willebrand disease","volume":"8","author":"de Wee","year":"2010","journal-title":"Journal of Thrombosis and Haemostasis: JTH"},{"issue":"7","key":"10.1016\/bs.apcsb.2025.08.010_bib39","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1111\/jth.15741","article-title":"Efanesoctocog alfa elicits functional clot formation that is indistinguishable to that of recombinant factor VIII","volume":"20","author":"Demers","year":"2022","journal-title":"Journal of Thrombosis and Haemostasis: JTH"},{"issue":"8","key":"10.1016\/bs.apcsb.2025.08.010_bib40","doi-asserted-by":"crossref","first-page":"17193","DOI":"10.3390\/ijms160817193","article-title":"Protein folding and mechanisms of proteostasis","volume":"16","author":"D\u00edaz-Villanueva","year":"2015","journal-title":"International Journal of Molecular Sciences"},{"issue":"9","key":"10.1016\/bs.apcsb.2025.08.010_bib41","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1021\/acs.jctc.4c00067","article-title":"A perspective on protein structure prediction using quantum computers","volume":"20","author":"Doga","year":"2024","journal-title":"Journal of Chemical Theory and Computation"},{"key":"10.1016\/bs.apcsb.2025.08.010_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadva.2023.100091","article-title":"Applications of fluorescence spectroscopy in protein conformational changes and intermolecular contacts","volume":"3","author":"Dos Santos Rodrigues","year":"2023","journal-title":"BBA Advances"},{"issue":"11","key":"10.1016\/bs.apcsb.2025.08.010_bib43","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1182\/blood-2013-02-483263","article-title":"Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A","volume":"122","author":"Eckhardt","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/bs.apcsb.2025.08.010_bib44","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrm1052","article-title":"Quality control in the endoplasmic reticulum","volume":"4","author":"Ellgaard","year":"2003","journal-title":"Nature Reviews. Molecular Cell Biology"},{"issue":"7","key":"10.1016\/bs.apcsb.2025.08.010_bib45","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/j.1538-7836.2004.00756.x","article-title":"Two novel mutations in EGF\u2010like domains of human factor IX dramatically impair intracellular processing and secretion","volume":"2","author":"Enjolras","year":"2004","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/bs.apcsb.2025.08.010_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.975803","article-title":"Immunogenicity and toxicity of AAV gene therapy","volume":"13","author":"Ertl","year":"2022","journal-title":"Frontiers in Immunology"},{"issue":"5","key":"10.1016\/bs.apcsb.2025.08.010_bib47","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1046\/j.1365-2516.1999.00317.x","article-title":"Haemophilia therapy: Assessing the cumulative risk of HIV exposure by cryoprecipitate","volume":"5","author":"Evatt","year":"1999","journal-title":"Haemophilia: the Official Journal of the World Federation of Hemophilia"},{"key":"10.1016\/bs.apcsb.2025.08.010_bib48","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/1471-2105-14-314","article-title":"Identification of properties important to protein aggregation using feature selection","volume":"14","author":"Fang","year":"2013","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/bs.apcsb.2025.08.010_bib49","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.omtm.2020.07.005","article-title":"Induction of ER stress by an AAV5 BDD FVIII construct is dependent on the strength of the hepatic-specific promoter","volume":"18","author":"Fong","year":"2020","journal-title":"Molecular Therapy Methods & Clinical Development"},{"issue":"5","key":"10.1016\/bs.apcsb.2025.08.010_bib50","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1050-1738(00)00070-0","article-title":"Activation of factor IX by factor XIa","volume":"10","author":"Gailani","year":"2000","journal-title":"Trends in Cardiovascular Medicine"},{"issue":"3","key":"10.1016\/bs.apcsb.2025.08.010_bib51","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/cge.13088","article-title":"Protein misfolding diseases: Prospects of pharmacological treatment","volume":"93","author":"G\u00e1mez","year":"2018","journal-title":"Clinical Genetics"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.08.010_bib52","first-page":"45","article-title":"AIDS in a patient with hemophilia receiving mainly cryoprecipitate","volume":"131","author":"Gerstein","year":"1984","journal-title":"Canadian Medical Association Journal"},{"issue":"7","key":"10.1016\/bs.apcsb.2025.08.010_bib53","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1111\/jth.12958","article-title":"Hemophilia B: Molecular pathogenesis and mutation analysis","volume":"13","author":"Goodeve","year":"2015","journal-title":"Journal of Thrombosis and Haemostasis: JTH"},{"issue":"3","key":"10.1016\/bs.apcsb.2025.08.010_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25031764","article-title":"Fluorescence-based protein stability monitoring-A review","volume":"25","author":"Gooran","year":"2024","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/bs.apcsb.2025.08.010_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1128641","article-title":"Hemophilia a subjects with an intron-22 gene inversion mutation show CD4(+) T-effector responses to multiple epitopes in FVIII","volume":"14","author":"Gunasekera","year":"2023","journal-title":"Frontiers in Immunology"},{"issue":"114","key":"10.1016\/bs.apcsb.2025.08.010_bib56","doi-asserted-by":"crossref","DOI":"10.3791\/54266","article-title":"Assays for the degradation of misfolded proteins in cells","author":"Guo","year":"2016","journal-title":"Journal of visualized experiments : JoVE"},{"issue":"8","key":"10.1016\/bs.apcsb.2025.08.010_bib57","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.3324\/haematol.2019.229047","article-title":"Vitamin K-dependent carboxylation of coagulation factors: Insights from a cell-based functional study","volume":"105","author":"Hao","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/bs.apcsb.2025.08.010_bib58","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.3389\/fimmu.2020.01498","article-title":"FVIII immunogenicity-bioinformatic approaches to evaluate inhibitor risk in non-severe hemophilia A","volume":"11","author":"Hart","year":"2020","journal-title":"Frontiers in Immunology"},{"issue":"3","key":"10.1016\/bs.apcsb.2025.08.010_bib59","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/jth.15182","article-title":"Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001-2018","volume":"19","author":"Hassan","year":"2021","journal-title":"Journal of Thrombosis and Haemostasis: JTH"},{"issue":"7","key":"10.1016\/bs.apcsb.2025.08.010_bib60","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.jtha.2024.04.010","article-title":"Ultra-Long factor VIII: A major step forward toward a hemophilia-free mind","volume":"22","author":"Hermans","year":"2024","journal-title":"Journal of Thrombosis and Haemostasis: JTH"},{"issue":"3","key":"10.1016\/bs.apcsb.2025.08.010_bib61","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/febs.16312","article-title":"A guide to studying protein aggregation","volume":"290","author":"Housmans","year":"2023","journal-title":"The FEBS Journal"},{"issue":"3","key":"10.1016\/bs.apcsb.2025.08.010_bib62","doi-asserted-by":"crossref","first-page":"174","DOI":"10.21037\/tp.2017.04.07","article-title":"Sports participation recommendations for patients with bleeding disorders","volume":"6","author":"Howell","year":"2017","journal-title":"Translational Pediatrics"},{"key":"10.1016\/bs.apcsb.2025.08.010_bib63","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.arr.2014.07.002","article-title":"Clearance of misfolded and aggregated proteins by aggrephagy and implications for aggregation diseases","volume":"18","author":"Hyttinen","year":"2014","journal-title":"Ageing Research Reviews"},{"key":"10.1016\/bs.apcsb.2025.08.010_bib64","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-1-62703-339-8_8","article-title":"Activated partial thromboplastin time","volume":"992","author":"Ignjatovic","year":"2013","journal-title":"Methods in Molecular Biology"},{"issue":"2","key":"10.1016\/bs.apcsb.2025.08.010_bib65","first-page":"45","article-title":"Experimental validation of a predicted microRNA within human FVIII gene","volume":"10","author":"Jalali-Qomi","year":"2021","journal-title":"Molecular Biology Research Communications"},{"issue":"6","key":"10.1016\/bs.apcsb.2025.08.010_bib66","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1016\/j.jtha.2024.03.002","article-title":"Whole F8 gene sequencing identified pathogenic structural variants in the remaining unsolved patients with severe hemophilia A","volume":"22","author":"Jourdy","year":"2024","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"4","key":"10.1016\/bs.apcsb.2025.08.010_bib67","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1160\/TH10-11-0762","article-title":"Characterisation of factor IX with a glycine-to-valine missense mutation at residue 190 in a patient with severe haemophilia B","volume":"105","author":"Kao","year":"2011","journal-title":"Thrombosis and Haemostasis"},{"issue":"12","key":"10.1016\/bs.apcsb.2025.08.010_bib68","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1016\/j.ymthe.2022.10.004","article-title":"Ectopic clotting factor VIII expression and misfolding in hepatocytes as a cause for hepatocellular carcinoma","volume":"30","author":"Kapelanski-Lamoureux","year":"2022","journal-title":"Molecular Therapy: the Journal of the American Society of Gene Therapy"},{"issue":"3","key":"10.1016\/bs.apcsb.2025.08.010_bib69","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/73464","article-title":"Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector","volume":"24","author":"Kay","year":"2000","journal-title":"Nature Genetics"},{"issue":"6","key":"10.1016\/bs.apcsb.2025.08.010_bib70","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1182\/blood.V66.6.1302.1302","article-title":"Proteolytic inactivation of blood coagulation factor IX by thrombin","volume":"66","author":"Kisiel","year":"1985","journal-title":"Blood"},{"key":"10.1016\/bs.apcsb.2025.08.010_bib71","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1182\/blood-2019-122817","article-title":"Mim8 - a Next-generation FVIII mimetic Bi-specific antibody - potently restores the hemostatic capacity in hemophilia a settings in vitro and in vivo","volume":"134","author":"Kjellev","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/bs.apcsb.2025.08.010_bib72","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood.2020006315","article-title":"Emicizumab for the treatment of acquired hemophilia A","volume":"137","author":"Knoebl","year":"2021","journal-title":"Blood"},{"key":"10.1016\/bs.apcsb.2025.08.010_bib73","series-title":"GeneReviews(\u00ae). University of Washington, Seattle","article-title":"Hemophilia A","author":"Konkle","year":"1993"},{"issue":"5","key":"10.1016\/bs.apcsb.2025.08.010_bib74","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s13205-020-2166-x","article-title":"Advances in protein misfolding, amyloidosis and its correlation with human diseases","volume":"10","author":"Kundu","year":"2020","journal-title":"3 Biotech"},{"issue":"6","key":"10.1016\/bs.apcsb.2025.08.010_bib75","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1529\/biophysj.104.049700","article-title":"Detection and characterization of aggregates, prefibrillar amyloidogenic oligomers, and protofibrils using fluorescence spectroscopy","volume":"88","author":"Lindgren","year":"2005","journal-title":"Biophysical Journal"},{"issue":"6","key":"10.1016\/bs.apcsb.2025.08.010_bib76","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1182\/blood.2022017871","article-title":"F9 mutations causing deletions beyond the serine protease domain confer higher risk for inhibitor development in hemophilia B","volume":"141","author":"Liu","year":"2023","journal-title":"Blood"},{"issue":"12","key":"10.1016\/bs.apcsb.2025.08.010_bib77","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1055\/a-2107-0702","article-title":"Comprehensive analysis of hemophilia a (CAHEA): Towards full characterization of the F8 gene variants by long-read sequencing","volume":"123","author":"Liu","year":"2023","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1016\/bs.apcsb.2025.08.010_bib78","first-page":"Vol. 128","article-title":"[7] Factor VIII and factor VIIIa","author":"Lollar","year":"1993"},{"issue":"14","key":"10.1016\/bs.apcsb.2025.08.010_bib79","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/bloodadvances.2018021345","article-title":"Gene therapy in hemophilia A: A cost-effectiveness analysis","volume":"2","author":"Machin","year":"2018","journal-title":"Blood Advances"},{"issue":"2","key":"10.1016\/bs.apcsb.2025.08.010_bib80","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/bjh.18420","article-title":"A phase 1b\/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia","volume":"200","author":"Mahlangu","year":"2023","journal-title":"British Journal of Haematology"},{"issue":"4","key":"10.1016\/bs.apcsb.2025.08.010_bib81","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/hae.12133","article-title":"Is haemophilia B less severe than haemophilia A?","volume":"19","author":"Mannucci","year":"2013","journal-title":"Haemophilia: the Official Journal of the World Federation of Hemophilia"},{"issue":"9","key":"10.1016\/bs.apcsb.2025.08.010_bib82","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1023\/B:BIRY.0000043539.07961.4c","article-title":"Protein folding, misfolding, and aggregation. Formation of inclusion bodies and aggresomes","volume":"69","author":"Markossian","year":"2004","journal-title":"Biochemistry (Moscow)"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.08.010_bib83","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ejh.13339","article-title":"Clinical utility and impact of the use of the chromogenic vs one-stage factor activity assays in haemophilia A and B","volume":"104","author":"Marlar","year":"2020","journal-title":"European Journal of Haematology"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.08.010_bib84","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41531-024-00708-z","article-title":"Misfolded protein deposits in Parkinson\u2019s disease and Parkinson\u2019s disease-related cognitive impairment, a [11C]PBB3 study","volume":"10","author":"Matarazzo","year":"2024","journal-title":"npj Parkinson\u2019s Disease"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.08.010_bib85","doi-asserted-by":"crossref","first-page":"11","DOI":"10.18388\/abp.2015_1056","article-title":"The factor VIII protein and its function","volume":"63","author":"Mazurkiewicz-Pisarek","year":"2016","journal-title":"Acta Biochimica Polonica"},{"key":"10.1016\/bs.apcsb.2025.08.010_bib86","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3389\/fimmu.2020.00476","article-title":"Escape or fight: Inhibitors in hemophilia A","volume":"11","author":"Merlin","year":"2020","journal-title":"Frontiers in Immunology"},{"issue":"7","key":"10.1016\/bs.apcsb.2025.08.010_bib87","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","article-title":"Clinical use of lentiviral vectors","volume":"32","author":"Milone","year":"2018","journal-title":"Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, UK"},{"issue":"9_","key":"10.1016\/bs.apcsb.2025.08.010_bib88","doi-asserted-by":"crossref","first-page":"29s","DOI":"10.1177\/1076029618807583","article-title":"A practical guide to the management of the fetus and newborn with hemophilia","volume":"24","author":"Moorehead","year":"2018","journal-title":"Clinical and Applied Thrombosis\/Hemostasis: Official Journal of the International Academy of Clinical and Applied Thrombosis\/Hemostasis"},{"issue":"5","key":"10.1016\/bs.apcsb.2025.08.010_bib89","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.semcdb.2011.04.002","article-title":"Misfolded protein aggregates: Mechanisms, structures and potential for disease transmission","volume":"22","author":"Moreno-Gonzalez","year":"2011","journal-title":"Seminars in Cell & Developmental Biology"},{"issue":"11","key":"10.1016\/bs.apcsb.2025.08.010_bib90","article-title":"Sports and children with hemophilia: Current trends","volume":"8","author":"Moretti","year":"2021","journal-title":"Children (Basel)"},{"key":"10.1016\/bs.apcsb.2025.08.010_bib91","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.thromres.2020.12.033","article-title":"AAV mediated gene therapy for haemophilia B: From the early attempts to modern trials","volume":"236","author":"Muczynski","year":"2024","journal-title":"Thrombosis Research"},{"issue":"22","key":"10.1016\/bs.apcsb.2025.08.010_bib92","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232214498","article-title":"Protein misfolding and aggregation in the brain: Common pathogenetic pathways in neurodegenerative and mental disorders","volume":"23","author":"Ochneva","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"issue":"4","key":"10.1016\/bs.apcsb.2025.08.010_bib93","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1055\/s-0037-1619052","article-title":"Discrepancy between one-stage and chromogenic factor VIII activity assay results can lead to misdiagnosis of haemophilia A phenotype","volume":"30","author":"Oldenburg","year":"2010","journal-title":"Hamostaseologie"},{"issue":"12","key":"10.1016\/bs.apcsb.2025.08.010_bib94","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1016\/j.jtha.2023.08.032","article-title":"Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia a in the phase 3 trial GENEr8-1","volume":"21","author":"O\u2019Mahony","year":"2023","journal-title":"Journal of Thrombosis and Haemostasis: JTH"},{"issue":"3","key":"10.1016\/bs.apcsb.2025.08.010_bib95","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/hae.12872","article-title":"Activation, activity and inactivation of factor VIII in factor VIII products","volume":"22","author":"Orfeo","year":"2016","journal-title":"Haemophilia: the official journal of the World Federation of Hemophilia"},{"issue":"2","key":"10.1016\/bs.apcsb.2025.08.010_bib96","doi-asserted-by":"crossref","first-page":"62","DOI":"10.32607\/20758251-2012-4-2-62-73","article-title":"Coagulation factor IX for hemophilia B therapy","volume":"4","author":"Orlova","year":"2012","journal-title":"Acta Naturae"},{"issue":"11","key":"10.1016\/bs.apcsb.2025.08.010_bib97","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"The New England Journal of Medicine"},{"issue":"22","key":"10.1016\/bs.apcsb.2025.08.010_bib98","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222212467","article-title":"Protein misfolding and aggregation: The relatedness between Parkinson\u2019s disease and hepatic endoplasmic reticulum storage disorders","volume":"22","author":"Padilla-God\u00ednez","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"issue":"2","key":"10.1016\/bs.apcsb.2025.08.010_bib99","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/rth2.12094","article-title":"Product type and other environmental risk factors for inhibitor development in severe hemophilia A","volume":"2","author":"Peyvandi","year":"2018","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"issue":"8","key":"10.1016\/bs.apcsb.2025.08.010_bib100","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1111\/j.1538-7836.2005.01367.x","article-title":"The promise and challenges of bioengineered recombinant clotting factors","volume":"3","author":"Pipe","year":"2005","journal-title":"Journal of Thrombosis and Haemostasis: JTH"},{"issue":"8","key":"10.1016\/bs.apcsb.2025.08.010_bib101","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"The New England Journal of Medicine"},{"issue":"10","key":"10.1016\/bs.apcsb.2025.08.010_bib102","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1055\/s-0044-1787734","article-title":"Field study and correlative studies of factor IX variant FIX-R338L in participants treated with fidanacogene elaparvovec","volume":"124","author":"Pittman","year":"2024","journal-title":"Thrombosis and Haemostasis"},{"issue":"2","key":"10.1016\/bs.apcsb.2025.08.010_bib103","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1538-7836.2009.03675.x","article-title":"Activated factor x cleaves factor VIII at arginine 562, limiting its cofactor efficiency","volume":"8","author":"Plantier","year":"2010","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/bs.apcsb.2025.08.010_bib104","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/978-3-030-67696-4_6","article-title":"Defects in protein folding and\/or quality control cause protein aggregation in the endoplasmic reticulum","volume":"59","author":"Poothong","year":"2021","journal-title":"Progress in Molecular and Subcellular Biology"},{"issue":"21","key":"10.1016\/bs.apcsb.2025.08.010_bib105","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1182\/blood.2019002867","article-title":"Factor VIII exhibits chaperone-dependent and glucose-regulated reversible amyloid formation in the endoplasmic reticulum","volume":"135","author":"Poothong","year":"2020","journal-title":"Blood"},{"key":"10.1016\/bs.apcsb.2025.08.010_bib106","article-title":"Emergent data influences the risk\/benefit assessment of hemophilia gene therapy using recombinant adeno-associated virus","volume":"10","author":"Puetz","year":"2023","journal-title":"Frontiers in Medicine (Lausanne)"},{"issue":"3","key":"10.1016\/bs.apcsb.2025.08.010_bib107","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/j.1460-2075.1985.tb03689.x","article-title":"The human genes for hemophilia a and hemophilia b flank the x chromosome fragile site at Xq27.3","volume":"4","author":"Purrello","year":"1985","journal-title":"The EMBO Journal"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.08.010_bib108","doi-asserted-by":"crossref","first-page":"4","DOI":"10.20892\/j.issn.2095-3941.2018.0055","article-title":"Next-generation sequencing and its clinical application","volume":"16","author":"Qin","year":"2019","journal-title":"Cancer Biology & Medicine"},{"key":"10.1016\/bs.apcsb.2025.08.010_bib109","series-title":"Clinical methods: The history, physical, and laboratory examinations","article-title":"Coagulation tests","author":"Raber","year":"1990"},{"issue":"22","key":"10.1016\/bs.apcsb.2025.08.010_bib110","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1182\/blood.2020008974","article-title":"Gene-produced FVIII: Measure for measure","volume":"136","author":"Ragni","year":"2020","journal-title":"Blood"},{"issue":"19","key":"10.1016\/bs.apcsb.2025.08.010_bib111","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1182\/blood.2022018661","article-title":"Innovations in RNA therapy for hemophilia","volume":"142","author":"Ragni","year":"2023","journal-title":"Blood"},{"issue":"51","key":"10.1016\/bs.apcsb.2025.08.010_bib112","doi-asserted-by":"crossref","first-page":"35947","DOI":"10.1039\/D3RA06476J","article-title":"Stabilization challenges and aggregation in protein-based therapeutics in the pharmaceutical industry","volume":"13","author":"Rahban","year":"2023","journal-title":"RSC Advances"},{"issue":"5","key":"10.1016\/bs.apcsb.2025.08.010_bib113","article-title":"The unfolded protein response: An overview","volume":"10","author":"Read","year":"2021","journal-title":"Biology (Basel)"},{"issue":"3","key":"10.1016\/bs.apcsb.2025.08.010_bib114","first-page":"341","article-title":"MicroRNA and Hemophilia-A disease: Bioinformatics prediction and experimental analysis","volume":"23","author":"Rezaei","year":"2021","journal-title":"Cell Journal"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.08.010_bib115","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-245474","article-title":"Symptomatic haemophilia A: Management during pregnancy and the postpartum period","volume":"15","author":"Rodrigues-Martins","year":"2022","journal-title":"BMJ Case Reports"},{"issue":"14","key":"10.1016\/bs.apcsb.2025.08.010_bib116","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22147647","article-title":"Gene therapy in hemophilia: Recent advances","volume":"22","author":"Rodr\u00edguez-Merch\u00e1n","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"issue":"9","key":"10.1016\/bs.apcsb.2025.08.010_bib117","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044505","article-title":"Chemical chaperones improve protein secretion and rescue mutant factor VIII in mice with hemophilia A","volume":"7","author":"Roth","year":"2012","journal-title":"PLoS ONE"},{"issue":"21","key":"10.1016\/bs.apcsb.2025.08.010_bib118","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1182\/blood.2020005450","article-title":"Clogging up the pipeline: Factor VIII aggregates","volume":"135","author":"Sabatino","year":"2020","journal-title":"Blood"},{"issue":"10","key":"10.1016\/bs.apcsb.2025.08.010_bib119","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/nrm3658","article-title":"Chaperone machines for protein folding, unfolding and disaggregation","volume":"14","author":"Saibil","year":"2013","journal-title":"Nature Reviews. Molecular Cell Biology"},{"key":"10.1016\/bs.apcsb.2025.08.010_bib120","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/bs.mie.2018.12.039","article-title":"Methods for measuring misfolded protein clearance in the budding yeast saccharomyces cerevisiae","volume":"619","author":"Samant","year":"2019","journal-title":"Methods in Enzymology"},{"issue":"3","key":"10.1016\/bs.apcsb.2025.08.010_bib121","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s13311-013-0191-8","article-title":"Gene therapy for misfolding protein diseases of the central nervous system","volume":"10","author":"San Sebastian","year":"2013","journal-title":"Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics"},{"issue":"5","key":"10.1016\/bs.apcsb.2025.08.010_bib122","first-page":"596","article-title":"The evolution of recombinant factor replacement for hemophilia","volume":"58","author":"Sankar","year":"2019","journal-title":"Transfusion and Apheresis Science: Official Journal of the World Apheresis Association: Official Journal of the European Society for Haemapheresis"},{"key":"10.1016\/bs.apcsb.2025.08.010_bib123","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.csbj.2020.05.026","article-title":"Computational prediction of protein aggregation: Advances in proteomics, conformation-specific algorithms and biotechnological applications","volume":"18","author":"Santos","year":"2020","journal-title":"Computational and Structural Biotechnology Journal"},{"issue":"8","key":"10.1016\/bs.apcsb.2025.08.010_bib124","article-title":"Comprehensive screening of genetic variants in the coding region of F8 in severe hemophilia a reveals a relationship with disease severity in a Colombian cohort","volume":"14","author":"Sarmiento Doncel","year":"2024","journal-title":"Life (Chicago, Ill.: 1978)"},{"issue":"7","key":"10.1016\/bs.apcsb.2025.08.010_bib125","article-title":"Next-generation sequencing technology: Current trends and advancements","volume":"12","author":"Satam","year":"2023","journal-title":"Biology (Basel)"},{"issue":"6","key":"10.1016\/bs.apcsb.2025.08.010_bib126","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrd818","article-title":"Bioequivalence and the immunogenicity of biopharmaceuticals","volume":"1","author":"Schellekens","year":"2002","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"7","key":"10.1016\/bs.apcsb.2025.08.010_bib127","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/j.1538-7836.2008.03001.x","article-title":"Validation of a composite score for clinical severity of hemophilia","volume":"6","author":"Schulman","year":"2008","journal-title":"Journal of Thrombosis and Haemostasis: JTH"},{"key":"10.1016\/bs.apcsb.2025.08.010_bib128","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1146\/annurev.pharmtox.051208.165340","article-title":"Targeting proteins for destruction by the ubiquitin system: Implications for human pathobiology","volume":"49","author":"Schwartz","year":"2009","journal-title":"Annual Review of Pharmacology and Toxicology"},{"issue":"5","key":"10.1016\/bs.apcsb.2025.08.010_bib129","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/hae.12662","article-title":"In silico analyses of missense mutations in coagulation factor VIII: identification of severity determinants of haemophilia A","volume":"21","author":"Sengupta","year":"2015","journal-title":"Haemophilia: the Official Journal of the World Federation of Hemophilia"},{"issue":"17","key":"10.1016\/bs.apcsb.2025.08.010_bib130","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1182\/blood.2019001292","article-title":"BIVV001, a new class of factor VIII replacement for hemophilia a that is independent of von willebrand factor in primates and mice","volume":"135","author":"Seth Chhabra","year":"2020","journal-title":"Blood"},{"key":"10.1016\/bs.apcsb.2025.08.010_bib131","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3389\/fmolb.2019.00020","article-title":"Protein misfolding and ER stress in Huntington\u2019s disease","volume":"6","author":"Shacham","year":"2019","journal-title":"Frontiers in Molecular Biosciences"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.08.010_bib132","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1182\/bloodadvances.2019001140","article-title":"Concizumab: A novel anti-TFPI therapeutic for hemophilia","volume":"5","author":"Shapiro","year":"2021","journal-title":"Blood Advances"},{"issue":"5","key":"10.1016\/bs.apcsb.2025.08.010_bib133","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23052762","article-title":"The molecular basis of FIX deficiency in hemophilia B","volume":"23","author":"Shen","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"issue":"29","key":"10.1016\/bs.apcsb.2025.08.010_bib134","doi-asserted-by":"crossref","first-page":"18735","DOI":"10.1016\/S0021-9258(17)32228-7","article-title":"Factor v and protein s as synergistic cofactors to activated protein c in degradation of factor VIIIa","volume":"269","author":"Shen","year":"1994","journal-title":"The Journal of Biological Chemistry"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.08.010_bib135","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000067272","article-title":"An ELISA assay for the detection of factor VIII antibodies - comparison with the conventional Bethesda assay in a large cohort of haemophilia samples","volume":"109","author":"Shetty","year":"2003","journal-title":"Acta Haematologica"},{"issue":"21","key":"10.1016\/bs.apcsb.2025.08.010_bib136","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","article-title":"Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A","volume":"374","author":"Shima","year":"2016","journal-title":"The New England Journal of Medicine"},{"issue":"5","key":"10.1016\/bs.apcsb.2025.08.010_bib137","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1136\/jmedgenet-2016-104072","article-title":"Single synonymous mutation in factor IX alters protein properties and underlies haemophilia B","volume":"54","author":"Simhadri","year":"2017","journal-title":"Journal of Medical Genetics"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.08.010_bib138","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/jth.14621","article-title":"The 3.2 \u00e5 structure of a bioengineered variant of blood coagulation factor VIII indicates two conformations of the C2 domain","volume":"18","author":"Smith","year":"2020","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"4","key":"10.1016\/bs.apcsb.2025.08.010_bib139","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3109\/10409238.2015.1050550","article-title":"How it all starts: Initiation of the clotting cascade","volume":"50","author":"Smith","year":"2015","journal-title":"Critical Reviews in Biochemistry and Molecular Biology"},{"issue":"5","key":"10.1016\/bs.apcsb.2025.08.010_bib140","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1016\/S2352-3026(23)00037-6","article-title":"Fitusiran prophylaxis in people with severe haemophilia a or haemophilia B without inhibitors (Atlas-A\/B): A multicentre, open-label, randomised, phase 3 trial","volume":"10","author":"Srivastava","year":"2023","journal-title":"The Lancet. Haematology"},{"issue":"11","key":"10.1016\/bs.apcsb.2025.08.010_bib141","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s00109-003-0464-5","article-title":"Protein aggregation and aggregate toxicity: New insights into protein folding, misfolding diseases and biological evolution","volume":"81","author":"Stefani","year":"2003","journal-title":"Journal of Molecular Medicine : Official Organ of the \"Gesellschaft Deutscher Naturforscher und \u00c4rzte\""},{"key":"10.1016\/bs.apcsb.2025.08.010_bib142","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jconrel.2019.02.009","article-title":"Long-term correction of hemophilia B using adenoviral delivery of CRISPR\/Cas9","volume":"298","author":"Stephens","year":"2019","journal-title":"Journal of Controlled Release: Official Journal of the Controlled Release Society"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.08.010_bib143","first-page":"11","article-title":"Detection of misfolded protein aggregates from a clinical perspective","volume":"2","author":"Str\u00f8mland","year":"2016","journal-title":"Journal of Clinical and Translational Research"},{"issue":"11","key":"10.1016\/bs.apcsb.2025.08.010_bib144","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1182\/blood-2010-09-307074","article-title":"Factor VIII A3 domain substitution N1922S results in hemophilia a due to domain-specific misfolding and hyposecretion of functional protein","volume":"117","author":"Summers","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/bs.apcsb.2025.08.010_bib145","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2183\/pjab.90.145","article-title":"Emerging novel concept of chaperone therapies for protein misfolding diseases","volume":"90","author":"Suzuki","year":"2014","journal-title":"Proceedings of the Japan Academy. Series B, Physical and Biological Sciences"},{"issue":"8","key":"10.1016\/bs.apcsb.2025.08.010_bib146","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2023.130381","article-title":"Factor VIII A3 domain residues 1793-1795 represent a factor IXa-interactive site in the tenase complex","volume":"1867","author":"Takeyama","year":"2023","journal-title":"Biochimica et Biophysica Acta. General Subjects"},{"issue":"3","key":"10.1016\/bs.apcsb.2025.08.010_bib147","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1021\/bi201731p","article-title":"Factor VIII light chain contains a binding site for factor x that contributes to the catalytic efficiency of factor xase","volume":"51","author":"Takeyama","year":"2012","journal-title":"Biochemistry"},{"issue":"9","key":"10.1016\/bs.apcsb.2025.08.010_bib148","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1089\/ars.2009.2490","article-title":"Protein misfolding and aggregation in Parkinson\u2019s disease","volume":"11","author":"Tan","year":"2009","journal-title":"Antioxidants & Redox Signaling"},{"issue":"6","key":"10.1016\/bs.apcsb.2025.08.010_bib149","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s11011-019-00465-6","article-title":"Bioinformatics classification of mutations in patients with mucopolysaccharidosis IIIA","volume":"34","author":"Tanwar","year":"2019","journal-title":"Metabolic Brain Disease"},{"issue":"5","key":"10.1016\/bs.apcsb.2025.08.010_bib150","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s40259-023-00615-4","article-title":"Evaluating gene therapy as a potential paradigm shift in treating severe hemophilia","volume":"37","author":"Thornburg","year":"2023","journal-title":"BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.08.010_bib151","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1111\/jth.12929","article-title":"Half-life extended factor VIII for the treatment of hemophilia A","volume":"13","author":"Tiede","year":"2015","journal-title":"Journal of Thrombosis and Haemostasis: JTH"},{"issue":"13","key":"10.1016\/bs.apcsb.2025.08.010_bib152","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1111\/jcmm.17741","article-title":"RNA sequencing suggests that non-coding RNAs play a role in the development of acquired haemophilia","volume":"27","author":"Tigu","year":"2023","journal-title":"Journal of Cellular and Molecular Medicine"},{"issue":"5","key":"10.1016\/bs.apcsb.2025.08.010_bib153","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.bpj.2014.07.026","article-title":"Misfolding of vWF to pathologically disordered conformations impacts the severity of von willebrand disease","volume":"107","author":"Tischer","year":"2014","journal-title":"Biophysical Journal"},{"key":"10.1016\/bs.apcsb.2025.08.010_bib154","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101730","article-title":"Unlocking the potential of non-coding RNAs in cancer research and therapy","volume":"35","author":"Uppaluri","year":"2023","journal-title":"Translational Oncology"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.08.010_bib155","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1242\/dmm.013474","article-title":"Mechanisms of protein-folding diseases at a glance","volume":"7","author":"Valastyan","year":"2014","journal-title":"Disease Models & Mechanisms"},{"issue":"5992","key":"10.1016\/bs.apcsb.2025.08.010_bib156","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/312337a0","article-title":"Structure of human factor VIII","volume":"312","author":"Vehar","year":"1984","journal-title":"Nature"},{"issue":"4","key":"10.1016\/bs.apcsb.2025.08.010_bib157","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2209226","article-title":"Efanesoctocog alfa prophylaxis for patients with severe hemophilia a","volume":"388","author":"von Drygalski","year":"2023","journal-title":"The New England Journal of Medicine"},{"issue":"21","key":"10.1016\/bs.apcsb.2025.08.010_bib158","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/bloodadvances.2019000811","article-title":"Etranacogene dezaparvovec (AMT-061 phase 2b): Normal\/near normal FIX activity and bleed cessation in hemophilia B","volume":"3","author":"Von Drygalski","year":"2019","journal-title":"Blood Advances"},{"issue":"19","key":"10.1016\/bs.apcsb.2025.08.010_bib159","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1182\/bloodadvances.2022008886","article-title":"Stable and durable factor IX levels in patients with hemophilia b over 3 years after etranacogene dezaparvovec gene therapy","volume":"7","author":"von Drygalski","year":"2023","journal-title":"Blood Advances"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.08.010_bib160","first-page":"1","article-title":"Coagulation factor VIII: Structure and stability","volume":"259","author":"Wang","year":"2003","journal-title":"International Journal of Pharmaceutics"},{"issue":"7","key":"10.1016\/bs.apcsb.2025.08.010_bib161","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/jth.14471","article-title":"Von willebrand factor sialylation-A critical regulator of biological function","volume":"17","author":"Ward","year":"2019","journal-title":"Journal of Thrombosis and Haemostasis: JTH"},{"issue":"5","key":"10.1016\/bs.apcsb.2025.08.010_bib162","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/SHK.0000000000000663","article-title":"Plasma transfusion: History, current realities, and novel improvements","volume":"46","author":"Watson","year":"2016","journal-title":"Shock (Augusta, Ga. )"},{"key":"10.1016\/bs.apcsb.2025.08.010_bib163","article-title":"Missense mutations near the N-glycosylation site of the A2 domain lead to various intracellular trafficking defects in coagulation factor VIII","volume":"7","author":"Wei","year":"2017","journal-title":"Scientific Reports"},{"issue":"4","key":"10.1016\/bs.apcsb.2025.08.010_bib164","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/labmed\/lmx050","article-title":"Coagulation testing in the core laboratory","volume":"48","author":"Winter","year":"2017","journal-title":"Laboratory Medicine"},{"key":"10.1016\/bs.apcsb.2025.08.010_bib165","article-title":"In situ genetic correction of F8 intron 22 inversion in hemophilia A patient-specific iPSCs","volume":"6","author":"Wu","year":"2016","journal-title":"Scientific Reports"},{"issue":"1","key":"10.1016\/bs.apcsb.2025.08.010_bib166","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12959-016-0106-0","article-title":"Current animal models of hemophilia: The state of the art","volume":"14","author":"Yen","year":"2016","journal-title":"Thrombosis Journal"},{"key":"10.1016\/bs.apcsb.2025.08.010_bib167","first-page":"8","article-title":"Mitochondria supply ATP to the ER through a mechanism antagonized by cytosolic Ca(2)","author":"Yong","year":"2019","journal-title":"Elife"},{"issue":"6","key":"10.1016\/bs.apcsb.2025.08.010_bib168","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1055\/s-0033-1349223","article-title":"Combined deficiency of coagulation factors v and VIII: An update","volume":"39","author":"Zheng","year":"2013","journal-title":"Seminars in Thrombosis and Hemostasis"},{"issue":"7","key":"10.1016\/bs.apcsb.2025.08.010_bib169","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1542\/pir.34.7.289","article-title":"Hemophilia: In review","volume":"34","author":"Zimmerman","year":"2013","journal-title":"Pediatrics in Review \/ American Academy of Pediatrics"}],"container-title":["Advances in Protein Chemistry and Structural Biology","Protein Misfolding Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876162325000689?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876162325000689?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T17:50:07Z","timestamp":1764093007000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876162325000689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9780443294143"],"references-count":169,"URL":"https:\/\/doi.org\/10.1016\/bs.apcsb.2025.08.010","relation":{},"ISSN":["1876-1623"],"issn-type":[{"type":"print","value":"1876-1623"}],"subject":[],"published":{"date-parts":[[2025]]}}}